191 related articles for article (PubMed ID: 18308661)
1. Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposal.
Davì MV; Bodei L; Ferdeghini M; Falconi M; Testoni M; Paganelli G; Oliani C; Lo Cascio V; Francia G
Endocr Pract; 2008 Mar; 14(2):213-8. PubMed ID: 18308661
[TBL] [Abstract][Full Text] [Related]
2. Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro.
Capello A; Krenning EP; Breeman WA; Bernard BF; Konijnenberg MW; de Jong M
Cancer Biother Radiopharm; 2003 Oct; 18(5):761-8. PubMed ID: 14629824
[TBL] [Abstract][Full Text] [Related]
3. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
[TBL] [Abstract][Full Text] [Related]
4. Different technical possibilities of post-therapeutic tandem 90Y/ /177Lu-DOTATATE imaging.
Kunikowska J; Bajera A; Sawicka M; Czwarnowski P; Pawłowicz B; Aksamit D; Pawlak D; Królicki L
Nucl Med Rev Cent East Eur; 2013; 16(2):70-4. PubMed ID: 24068636
[TBL] [Abstract][Full Text] [Related]
5. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.
Kwekkeboom DJ; Bakker WH; Kooij PP; Konijnenberg MW; Srinivasan A; Erion JL; Schmidt MA; Bugaj JL; de Jong M; Krenning EP
Eur J Nucl Med; 2001 Sep; 28(9):1319-25. PubMed ID: 11585290
[TBL] [Abstract][Full Text] [Related]
6. Cushing's syndrome from ectopic production of corticotropin by a metastatic gastrinoma.
Babu AR; Dwarakanathan AA
Endocr Pract; 2003; 9(3):229-32. PubMed ID: 12917066
[TBL] [Abstract][Full Text] [Related]
7. Ectopic Corticotropin-Producing Neuroendocrine Tumor of the Pancreas Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.
Makis W; McCann K; Riauka TA; McEwan AJ
Clin Nucl Med; 2016 Jan; 41(1):50-2. PubMed ID: 26359569
[TBL] [Abstract][Full Text] [Related]
8. Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome.
Zandee WT; Brabander T; Blažević A; Minczeles NS; Feelders RA; de Herder WW; Hofland J
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3665-e3672. PubMed ID: 33942075
[TBL] [Abstract][Full Text] [Related]
9. Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+.
Breeman WA; De Jong MT; De Blois E; Bernard BF; De Jong M; Krenning EP
Nucl Med Biol; 2004 Aug; 31(6):821-4. PubMed ID: 15246375
[TBL] [Abstract][Full Text] [Related]
10. Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.
Zandee WT; Brabander T; Blažević A; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; de Herder WW
J Clin Endocrinol Metab; 2019 Apr; 104(4):1336-1344. PubMed ID: 30566620
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
12. Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
De Jong M; Bernard BF; De Bruin E; Van Gameren A; Bakker WH; Visser TJ; Mäcke HR; Krenning EP
Nucl Med Commun; 1998 Mar; 19(3):283-8. PubMed ID: 9625504
[TBL] [Abstract][Full Text] [Related]
13. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.
de Jong M; Bakker WH; Krenning EP; Breeman WA; van der Pluijm ME; Bernard BF; Visser TJ; Jermann E; Béhé M; Powell P; Mäcke HR
Eur J Nucl Med; 1997 Apr; 24(4):368-71. PubMed ID: 9096086
[TBL] [Abstract][Full Text] [Related]
14. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
Kunikowska J; Królicki L; Hubalewska-Dydejczyk A; Mikołajczak R; Sowa-Staszczak A; Pawlak D
Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1788-97. PubMed ID: 21553086
[TBL] [Abstract][Full Text] [Related]
15. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.
Bodei L; Handkiewicz-Junak D; Grana C; Mazzetta C; Rocca P; Bartolomei M; Lopera Sierra M; Cremonesi M; Chinol M; Mäcke HR; Paganelli G
Cancer Biother Radiopharm; 2004 Feb; 19(1):65-71. PubMed ID: 15068613
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.
Kwekkeboom DJ; Teunissen JJ; Bakker WH; Kooij PP; de Herder WW; Feelders RA; van Eijck CH; Esser JP; Kam BL; Krenning EP
J Clin Oncol; 2005 Apr; 23(12):2754-62. PubMed ID: 15837990
[TBL] [Abstract][Full Text] [Related]
17. Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate.
Bakker WH; Breeman WA; Kwekkeboom DJ; De Jong LC; Krenning EP
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):265-71. PubMed ID: 17043624
[TBL] [Abstract][Full Text] [Related]
18. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model.
Norenberg JP; Krenning BJ; Konings IR; Kusewitt DF; Nayak TK; Anderson TL; de Jong M; Garmestani K; Brechbiel MW; Kvols LK
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):897-903. PubMed ID: 16467104
[TBL] [Abstract][Full Text] [Related]
19. Nephrotoxicity after PRRT - still a serious clinical problem? Renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATATE and 90Y/177Lu-DOTATATE.
Kunikowska J; Królicki L; Sowa-Staszczak A; Pawlak D; Hubalewska-Dydejczyk A; Mikołajczak R
Endokrynol Pol; 2013; 64(1):13-20. PubMed ID: 23450442
[TBL] [Abstract][Full Text] [Related]
20. Extraventricular neurocytoma treated with 177Lu DOTATATE PRRT induction and maintenance therapies.
Makis W; McCann K; McEwan AJ
Clin Nucl Med; 2015 Mar; 40(3):234-6. PubMed ID: 25608145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
